Bacteria have evolved ways to evade the use of antimicrobials, leading to the rise of multidrug-resistant bacteria. This is particularly true in the case of Gram-Negative bacteria such as Acinetobacter baumannii, Klebsiella pneumoniae, E.coli
and Pseudomonas aeruginosa.
Given the high unmet medical need and the dwindling number of effective antibiotics, Bioharmony Therapeutics is developing a pipeline of lysins for infections caused by multidrug-resistant Gram-Negative bacteria.